1 / 8Russian Direct Investment Fund (RDIF) and Indian pharma company Hetero, have agreed to produce in India over 100 million doses per year of Sputnik V covid vaccine in India, Russia's sovereign wealth fund said.2 / 8The production of the Russian covid vaccine is expected start in the beginning of 2021. “We are pleased to collaborate with RDIF as a manufacturing partner for the most anticipated Sputnik V vaccine for the treatment of Covid-19. 3 / 8While we look forward to the clinical trial results in India, we believe that manufacturing the product locally is crucial to enable swift access to patients,' B. Murali Krishna Reddy, Director – International Marketing, Hetero Labs Limited commented.4 / 8RDIF on November 24 had announced positive results obtained during the second interim data analysis of the largest double-blind, randomized, placebo-controlled Phase III clinical trials in Russia involving 40,000 volunteers.5 / 8Kirill Dmitriev, CEO of the Russian Direct Investment Fund, in a statement said: “We are delighted to announce the agreement between RDIF and Hetero that will pave the way to production of the safe and highly effective Sputnik V vaccine on Indian soil. 6 / 8The vaccine’s interim clinical trial results show 95% efficacy on the 42nd day after the first dose. Thanks to our cooperation with Hetero, we will be able to significantly increase production capacity and provide people of India with an efficient solution in this challenging period of the pandemic.'7 / 8Since November 9, four drug makers have announced that their vaccines work, most of them more than 90% of the time.8 / 8The first to report Phase 3 results was the US-German collaboration between pharmaceutical giant Pfizer and German biotech start-up BioNTech, followed by the US firm Moderna, a British partnership between AstraZeneca and Oxford University, and Russia's state-run Gamaleya Research Institute of Epidemiology and Microbiology which has developed the Sputnik V vaccine.